The first steps towards developing a vaccine against an insidious sexual transmitted infection (STI) have been accomplished by researchers at McMaster University.
Researchers at the Michael G. DeGroote Institute for Infectious Disease Research at McMaster have developed the first widely protective vaccine against chlamydia, a common STI that is mostly asymptomatic but impacts 113 million people around the world each year and can result in infertility.
In a study, recently published in the journal Vaccine, the researchers show that a novel chlamydial antigen known as BD584 is a potential vaccine candidate for the most common species of chlamydia known as Chlamydia trachomatis.
As most C. trachomatis infections are asymptomatic, chlamydia can often go untreated and lead to upper genital tract infections, pelvic inflammatory disease, and infertility. This is why the promise of a vaccine would be extremely beneficial, says David Bulir, co-author of the study.
“Vaccine development efforts in the past three decades have been unproductive and there is no vaccine approved for use in humans,” said Bulir, who just finished his PhD in medical sciences at McMaster.
“Vaccination would be the best way to way to prevent a chlamydia infection, and this study has identified important new antigens which could be used as part of a vaccine to prevent or eliminate the damaging reproductive consequences of untreated infections.”
In the research team’s study, BD584 was able to reduce chlamydial shedding – a symptom of C. trachomatis – by 95 per cent. The antigen also decreased hydrosalpinx, another C. trachomatis symptom which involves fallopian tubes being blocked with serous fluids, by 87.5 per cent.
The results look very promising, said senior author James Mahony, a professor of Pathology and Molecular Medicine for McMaster’s Michael G. DeGroote School of Medicine and a researcher at St. Joseph Healthcare Hamilton’s Research Institute where the work was performed.
Co-author and McMaster PhD student, Steven Liang, explains, “not only is the vaccine effective, it also has the potential to be widely protective against all C. trachomatis strains, including those that cause trachoma.”
Trachoma is an eye infection caused by chlamydia and is the leading cause of preventable blindness affecting millions of people in many resource-poor regions of the world.
“The vaccine would be administered through the nose. This is easy and painless and does not require highly trained health professionals to administer, and that makes it an inexpensive solution for developing nations,” he said.
The next step is more testing for effectiveness against different strains of Chlamydia and in different formulations. The study was funded by the Canadian Institutes for Health Research.
The Latest on: Chlamydia
via Google News
The Latest on: Chlamydia
- Study evaluates the use of flow cytometry in diagnosing male urethritison December 3, 2020 at 4:41 pm
According to the World Health Organization, the global prevalence estimates of sexually transmitted infections for men in 2016 were 2.7% for chlamydia, 0.7% for gonorrhea and 0.6% for trichomoniasis.
- A new era is dawning in diagnosing sexually transmitted infections in menon December 3, 2020 at 9:24 am
According to the World Health Organization, the global prevalence estimates of sexually transmitted infections for men in 2016 were 2.7% for chlamydia, 0.7% for gonorrhea, and 0.6% for trichomoniasis.
- The Chlamydia Knowledge, Awareness and Testing Practices of Australian General Practitioners and Practice Nurseson December 1, 2020 at 4:00 pm
The Australian Government has funded the Australian Chlamydia Control Effectiveness Pilot (ACCEPt), a cluster randomised controlled trial of annual chlamydia testing in 16–29 year old males and ...
- Sexually transmitted infections can wreak havoc on reproductionon November 30, 2020 at 9:26 pm
The commonly known STIs are chlamydia and gonorrhea. The rates of these infections have increased in recent years, raising concerns in public health circles. Chlamydia tends to run a silent course ...
- Advances in Sampling and Screening for Chlamydiaon November 30, 2020 at 4:01 pm
Chlamydia is the most commonly diagnosed bacterial sexually transmitted infection in the developed world, with diagnosis rates continuing to increase each year. As chlamydia is largely ...
- Chlamydia: the factson November 30, 2020 at 4:01 pm
Chlamydia is a very common disease, which is primarily transmitted through sexual intercourse. It is known as the silent infection because it is often symptomless and can lie dormant for up to 20 ...
- Global Chlamydia Infection Diagnostics and Therapeutics Industryon November 30, 2020 at 6:55 am
utm_source=PRN Amid the COVID-19 crisis, the global market for Chlamydia Infection Diagnostics and Therapeutics estimated at US$1.4 Billion in the year 2020, is projected to reach a revised size ...
- Global Chlamydia Infection Diagnostics and Therapeutics Industryon November 30, 2020 at 6:51 am
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.
- Chlamydia Diagnosis and Treatment Market Potential, Sales Catalog and Research Process Methodology | Abbott Laboratories, Hologic, LabCorpon November 29, 2020 at 11:42 pm
New York City, NY: Nov. 30, 2020 – Published via (Wired Release)- Global Chlamydia Diagnosis and Treatment 2021-2030 | Investment Opportunity Pivot on Hospitals, Diagnostic centres, Research ...
- What Causes Chlamydia?on November 9, 2020 at 4:00 pm
Chlamydia is a sexually transmitted infection (STI) that can affect anyone. It’s treatable, but it can lead to serious complications if treatment isn’t sought. You can get chlamydia by having ...
via Bing News